Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Clinicopath Conf, Dopamine-Responsive-Dystonia Caused by a Mutation in the GCH1 Gene
NEJM 355:831-839, Case 26-2006, 2006
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Random, Placebo-Contr Study of Tolcapone in Pts with Fluctuating Parkinson Dis Trtd With Levodopa-Carbidopa
Arch Neurol 55:1089-1095, Adler,C.H.,et al, 1998
Standard & Controlled-Release Levodopa/Carbidopa in Fluctuating Parkinson's Disease on a Protein Redistribution Diet
Arch Neurol 48:402-405, Karstaedt,P.J.,et al, 1991
Bromocriptine in Parkinson Disease:Further Studies
Neurol 29:363-369, Lieberman,A.N.,et al, 1979
Comparative Effectiveness of Two Extracerebral DOPA Decarboxylase Inhibitors in Parkinson Disease
Neurol 28:964-968, Lieberman,A.,et al, 1978
Drug Therapy of Parkinsonism
NEJM 295:814, Bianchine,J.R., 1976